Safety of cerebral angiography and neuroendovascular therapy in patients with chronic kidney disease

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Purpose: Contrast-induced nephropathy is a common clinical concern in patients undergoing neuroendovascular procedures, especially in those with pre-existent kidney disease. We aimed to define the incidence of contrast-induced nephropathy in these high-risk patients in our practice. Methods: We analyzed data retrospectively from patients undergoing neuroendovascular procedures at two academic medical centers over a 4-year period. Contrast-induced nephropathy was determined by an absolute increase in serum creatinine of 0.5 mg/dL or a rise from its baseline value by ≥ 25%, at 48–72 h after exposure to contrast agent after excluding other causes of renal impairment. High-risk patients were identified as those with pre-procedural estimated glomerular filtration rate < 60 mL/min irrespective of creatinine level, corresponding to stages 3–5 of chronic kidney disease. Results: One hundred eighty-five high-risk patients undergoing conventional cerebral angiography and neuroendovascular interventions were identified. Only 1 out of 184 (0.54%) high-risk patients developed contrast-induced nephropathy. That one patient had stage 5 chronic kidney disease and multiple other risk factors. Conclusion: We have observed a very low rate of renal injury in patients with chronic kidney disease, traditionally considered high risk for neuroendovascular procedures. Multiple factors may be responsible in the risk reduction of contrast-induced nephropathy in this patient population.

Original languageEnglish (US)
Pages (from-to)529-533
Number of pages5
Issue number5
StatePublished - May 1 2018

Bibliographical note

Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.


  • Angiography
  • Chronic kidney disease
  • Contrast-induced nephropathy
  • Neuroendovascular


Dive into the research topics of 'Safety of cerebral angiography and neuroendovascular therapy in patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this